Tradestie Institutional Equity Comparison Engine
ABCL vs QQEW โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABCL Overall Edge
ABCL Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to AbCellera Biologics Inc. Common Shares (ABCL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ABCL trades at 27.6x Forward P/E with -1550.0% operating margin (-76.3% YoY revenue) versus QQEW at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, ABCL sits in CONSOLIDATION (25th %ile IV; Dealer Gamma Walls on Pro) against QQEW sits in UNCLASSIFIED (86th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ABCL
ABCL 27.6x vs QQEW N/M Fwd P/E
Growth & Margin Winner
ABCL
Op Margin -1550.0% vs N/A ยท YoY -76.3% vs N/A
Momentum & Technical Winner
ABCL
1Y +209.0% vs +4.1% ยท 52W Pos 69% vs 52%
Options & Structure Winner
ABCL
CONSOLIDATION (25th %ile IV) vs UNCLASSIFIED (86th %ile IV)
ABCL
NASDAQ
AbCellera Biologics Inc. Common Shares
Pharmaceutical Preparations
$11.19
-2.65% 1D
Market Cap
$3.8B
1M Return
-5.21%
1Y Return
+208.98%
Forward P/E
27.6x
Unified AI Score
60.7 / 100
BUY
Tech 52.0
Fund 59.0
Flow 67.0
Mom 54.0
QQEW
NASDAQ
First Trust NASDAQ-100 Equal Weighted Index Fund
Institutional Equity
$145.79
-2.13% 1D
Market Cap
N/A
1M Return
-5.73%
1Y Return
+4.1%
Forward P/E
N/M
Unified AI Score
58.9 / 100
HOLD
Tech 75.0
Fund 60.0
Flow 50.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ABCL +208.98%
QQEW +4.1%
Spread: +204.88 pp (ABCL Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ABCL TTM Op. Margin: -1550.0%
QQEW TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABCL vs QQEW. Trailing 12-month operating profitability (ABCL -1550.0% vs QQEW N/A) and valuation multiples (ABCL 27.6x vs QQEW N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ABCL | QQEW | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.8B | N/A | Larger Scale | ABCL |
| Trailing P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Forward P/E Ratio Valuation | 27.6x | N/M | Lower Multiple | ABCL |
| Revenue Growth (YoY) Growth | -76.3% | N/A | Higher Growth | ABCL |
| Operating Margin (TTM) Profitability | -1550.0% | N/A | Higher Margin | ABCL |
| Net Profit Margin Profitability | -248.8% | N/A | Higher Margin | ABCL |
| Return on Equity (ROE) Capital Efficiency | -17.3% | N/A | Higher ROE | ABCL |
| 52-Week Range Position Momentum | 69% ($3โ$15) | 52% ($122โ$167) | Stronger Trend | ABCL |
| Beta / 30D Volatility Risk Regime | 2.31ฮฒ ยท 87% Vol | 1.33ฮฒ ยท 34% Vol | Lower Realized Risk | QQEW |
| Unified Institutional Score Composite Signal | 60.7 / 100 (BUY) | 58.9 / 100 (HOLD) | Higher Composite | ABCL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ABCL vs QQEW Buy Guide
ABCL
CONSOLIDATION
34d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Compressed (<25th %ile)
QQEW
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
86th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ABCL nor QQEW registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.